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Amyotrophic lateral sclerosis (ALS) is a clinical subtype of motor neurone disease
(MND), a fatal neurodegenerative disease involving the loss of both the upper and lower
motor neurones from the motor cortex, brainstem, and spinal cord. Identifying specific
disease biomarkers would help to not only improve diagnostic delay but also to classify
disease subtypes, monitor response to therapeutic drugs and track disease progression.
miRNAs are small non-coding RNA responsible for regulating gene expression and
ultimately protein expression and have been used as biomarkers for many cancers and
neurodegenerative disorders. Investigating the detection of miRNAs in cerebrospinal
fluid (CSF), the fluid that bathes the central nervous system (CNS) is a prime target
for identifying potential biomarkers for ALS. This is the first study to investigate the
expression of miRNAs in the CSF of ALS patients using small RNA sequencing. We
detected 11 differentially expressed miRNAs in the CSF of sporadic ALS (sALS) patients
related to neural and glial activity. Additionally, miRNAs involved in glucose metabolism
and the regulation of oxidative stress were also identified. Detecting the presence of
potential CSF derived miRNA biomarkers in sALS could open up a whole new area of
knowledge to help gain a better understanding of disease pathophysiology. Additionally,
with further investigation, the tracking of CSF miRNA over the disease course could be
used to follow the disease progression and monitor the effect of novel therapeutics that
could be personalized to an individual disease phenotype.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common clinical subtype of motor neurone disease
(MND), a fatal neurodegenerative disease involving the loss of both the upper and lower motor
neurones from the motor cortex, brainstem, and spinal cord. Motor neurone loss in ALS leads
to progressive muscle wasting and weakness, with eventual death, in the majority of cases due to
respiratory failure, within 2–3 years from symptom onset.
Waller et al. miRNAs in ALS CSF Samples
Diagnosing ALS can be difficult, with the disease showing
substantial clinical and prognostic heterogeneity (Benatar and
Wuu, 2012). Many ALS symptoms are typical of other similarly
presented diseases such as myopathy, neuropathy, structural
spinal disorders and myasthenia gravis (MG) (Ghasemi, 2016).
Therefore, identifying specific disease biomarkers would help to
not only diagnose ALS but also help to classify disease subtypes,
monitor a patient’s response to therapeutic drugs and track
disease progression.
Our recently published paper shows the potential use of
serum-based microRNAs (miRNAs) as biomarkers of ALS
disease progression (Waller et al., 2017). miRNAs are small
non-coding RNAs responsible for regulating gene expression
and ultimately protein expression. Around 70% of miRNAs
are expressed in the brain, with many being brain-specific
or brain-enriched (Muller et al., 2014). Investigating miRNAs
in cerebrospinal fluid (CSF), the fluid that bathes the central
nervous system (CNS) is a prime target biosample for identifying
potential biomarkers for ALS. miRNAs present in CSF are
increasingly being used as robust prognostic and diagnostic
biomarkers in cancer (Drusco et al., 2015; Akers et al., 2017). In
addition miRNA dysregulation in the CSF has frequently been
reported in a range of neurological disorders including multiple
sclerosis (MS) (Bergman et al., 2016; Quintana et al., 2017),
Alzheimer’s Disease (AD) (Denk et al., 2015; Sorensen et al.,
2016), Parkinson’s Disease (PD) (Gui et al., 2015; Marques et al.,
2016) and ALS (Freischmidt et al., 2013; Benigni et al., 2016).
Plasma, urine and saliva have been investigated as potential
sources of disease biomarkers, however, miRNA biomarkers
identified in the CSF may reflect changes in the degenerating
cells, or could be markers reflecting pathophysiological changes
in the brain, representing a more sensitive indicator of brain
pathology than those present in blood or other biofluids.
Only three previous publications have investigated miRNA
expression in CSF from patients with AD and PD using small
RNA sequencing (Burgos et al., 2013, 2014; Yagi et al., 2017). This
is the first study to investigate miRNA expression in CSF derived
from ALS patients using small RNA sequencing. We identify
several differentially expressed miRNAs in sporadic ALS (sALS)
patient CSF samples compared to control subjects. Following
qPCR validation, we discuss the challenges of these experiments
in CSF studies. Overall, identifying the presence of potential
miRNA biomarkers in sALS CSF samples is a promising tool that,
with further investigation, could open up a whole new area of
knowledge to help gain a better understanding of the disease.
MATERIALS AND METHODS
The pipeline methods are depicted as a flowchart in Figure 1.
Sample Collection and Patient Data
CSF was collected at the Royal Hallamshire Hospital Sheffield,
and all laboratory work was conducted at the Sheffield
Institute for Translational Neuroscience (SITraN). This
study (12/YH/0330) was carried out in accordance with the
recommendations of NRES Committee Yorkshire & The
Humber - Sheffield with written informed consent from
all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the NRES Committee Yorkshire & The Humber
- Sheffield. CSF samples were obtained by lumbar puncture,
held on ice and processed within 1 h by centrifugation at
800 g for 5min to pellet cellular debris. The supernatant was
removed, snap frozen and stored in liquid nitrogen prior to RNA
extraction. We obtained CSF samples from the following three
groups: sALS (n = 32), healthy controls (n = 10), neurological
disease controls; multiple sclerosis (MS) patients (n = 6). Due
to the limited availability of CSF samples obtained from healthy
control subjects these were combined with CSF samples obtained
from a group of neurological disease control subjects (MS
Patients) for all downstream analyses forming a “combined
control” cohort (n = 16), see results section for justification. An
overview of the sample cohort is included in Table 1.
RNA Extraction and Quality Control qPCR
Total RNA was extracted from 1ml of CSF from each subject
using the miRVana PARIS kit (Thermo Fisher Scientific)
according to the manufacturer’s instructions following the Total
RNA Isolation Procedure with minor modifications; (1) As the
yield of miRNAs in CSF was expected to be lower than other
biofluid samples, 2 µl of glycogen (20 µg/µL) was added to each
sample prior to total RNA extraction to enhance the binding of
RNA to the column (McAlexander et al., 2013). (2) To control
for variations of RNA extraction, each sample was spiked with
5 µl of 5 nM synthetic Caenorhabditis elegans microRNA 39
(Syn-cel-miR-39) (Qiagen).
Following extraction, it was not possible to quantify the
miRNA concentration of CSF samples using the Nanodrop
therefore, equivalent CSF volumes were used as input for the
RNA extraction (Muller et al., 2014). Small RNA Bioanalyzer
(Agilent) chips were used to identify the presence of miRNAs in
the extracted samples (Supplementary Figure 1A). The Qiagen
miScript PCR System was used to measure the recovery of small
RNAs in each of the samples according to the cel-miR-39 spike-
in concentration. Briefly, 5 µl of extracted RNA was reverse
transcribed using the miScript II Reverse Transcription (RT) kit
according to manufacturer’s instructions (37◦C for 60min, 95◦C
for 5min, followed by a 5min incubation on ice). cDNA was
diluted 5-fold in RNase-free water and added to the miScript
qPCR reaction mix containing 2x QuantiTect SYBR Green PCR
master mix (MM), universal primer and a specific cel-miR-
39 miRNA primer assay. Amplification was performed using a
CFX384 BioRad Real-Time PCR System with a denaturation step
at 95◦C for 15 mins, followed by 40 cycles at 94◦C for 15 s, 55◦C
for 30 s and 70◦C for 30 s.
Small RNA-Sequencing
RNA was prepared for small RNA-sequencing using the Illumina
TruSeq Small RNA library preparation kit following a modified
protocol as described in Burgos et al. (2013). Briefly, T4 RNA
ligase was used to ligate RA5 and RA3 RNA oligonucleotides
to the 5′ and 3′ ends of miRNA within 5 µl of extracted total
RNA respectively. Adapter-ligated RNA was reverse transcribed
to generate a cDNA library and amplified following 15 cycles
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FIGURE 1 | CSF small RNA sequencing methodology and data analysis workflow. This workflow begins with RNA extraction from CSF samples using the miRVana
PARIS RNA extraction kit. The proceeding quality control (QC) steps performed prior to small RNA sequencing include the running of a small RNA Bioanalyzer chip and
qPCR for the cel-miR-39 spike-in. The extracted RNA was subjected to Illumina TruSeq library preparation and gel purification and subsequent QC steps prior to small
RNA sequencing. Initial sequencing data was put through the Illumina Sequencing Analysis Viewer to establish the Phred Quality score (Q > 30). Following this the raw
.bcl generated image files were de-multiplexed and converted to .fastq text files where initial QC testing was carried out in Chimira to establish the distribution of read
counts amongst each sequenced sample and identify any outlier samples. Both Oasis 2.0 and Genboree platforms were used to identify the specific miRNA content in
each sample prior to using DEseq2 in both platforms to determine differential expressed miRNAs in sALS patients compared to control subjects (p ≤ 0.05). Based on
comparing the commonly expressed and uniquely significant miRNA between each analysis platform individual miRNAs were chosen for validation via miScript qPCR.
TABLE 1 | Patient cohort.
sALS (n = 32) Headache/migraine controls (n = 10) MS (n = 6) Combined Controls (n = 16)
Mean age (range) 61.3 (40–84) 53.9 (37–81) 58.0 (54–69) 55.3 (37–81)
Gender (male:female) 21:11 3:7 3:3 6:10
sALS, sporadic amyotrophic lateral sclerosis.
of PCR (denaturation at 98◦C for 30 s the products were
amplified following 15 cycles at 98◦C for 10 s, 60◦C for 30 s,
72◦C for 15 s and then 72◦C for 10min) incorporating individual
barcodes to each sample to enable the pooling and loading
of multiple samples onto the Illumina HiScanSQ. Individual
cDNA library products of 140–160 bp were isolated on a
6% TBE PAGE gel (Supplementary Figure 1B). The quality of
the each generated small RNA-sequencing cDNA library was
assessed using High Sensitivity DNA chips on the Agilent 2100
Bioanalyzer (Supplementary Figure 1C). For cluster generation
1000 pM of each cDNA library from 12 samples (8 sALS and 4
controls) were pooled together and loaded onto two lanes of the
flow cell at 20 pM concentration per lane. Each sample pool was
loaded across two lanes of the flow cell to maximize the number
of mapped reads (50 bp single read). 1% PhiX was spiked into
each lane of the flow cell as a sequencing control. We processed
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our samples using the Illumina TruSeq SBS Kit (v3) for 51 cycles
of sequencing and for 7 cycles of the indexing read.
Sequencing Data Analysis
Initial quality control (QC) testing of post-sequencing data was
carried out using the Illumina Sequencing Analysis Viewer to
identify the Illumina Phred quality score (>Q30) and pass
filter (PF) reads. Illumina sequencers perform an internal
quality filtering procedure called chastity filter, and reads
that pass this filter are called PF removing the least reliable
clusters from the image analysis results. Sequence data were
converted from the generated image.bcl files to raw, de-
multiplexed sequencing data in the.fastq text file format using
the Illumina developed bcl2fastq pipeline. Raw sequencing data
was deposited at NCBI’s Gene Expression Omnibus (accession
number GSE105811). Further QC testing of the raw data
was completed using Chimira, a web-based system used for
miRNA analysis from small RNA-sequencing data (Vitsios and
Enright, 2015). Briefly, the 3′ adapter sequences were trimmed
and the overall miRNA reads counted. Following QC, the
individual sample data were uploaded into two independent
online software packages designed for analyzing in detail small
RNA-sequencing data; Oasis 2.0 (Love et al., 2014; Capece
et al., 2015) and Genboree (Riehle et al., 2012; Coarfa et al.,
2014; Subramanian et al., 2015). Specific trimming tools in
each of these packages enabled the removal of the Illumina
TruSeq 3′ adapter (TGGAATTCTCGGGTGCCAAGG) sequence
from each sample’s.fastq file and the read size filtered (15–
32 nt) with low abundance reads (<5 reads) discarded. All
remaining reads were mapped to the Human genome (Oasis
2.0: hg38, Genboree: Hg19) and miRBase_v21. Both packages
were then used to calculate the differential miRNA expression
using DESeq2 between control and sALS samples. The DESeq2
method is used for differential analysis of count data, using
shrinkage estimation for dispersions and fold changes to improve
stability and data interpretation (Love et al., 2014). The method
is based on negative binomial distribution, with custom fit
for variance-mean dependence (Anders and Huber, 2010). The
DESeq2 statistical analysis accounts for small replicate numbers,
discreteness, large dynamic range of data and the presence
of outliers (Love et al., 2014). Spearman’s rank correlation
coefficient was used to assess the relationship between age and
miRNA read count on both Genboree and Oasis generated data,
across the 15 candidate miRNAs. Additional non-parametric
Mann-Whitney tests were used to assess the differences between
miRNA read counts and gender.
qPCR Validation
For validation, individual cDNA samples from the initial QC
testing of extracted CSF samples were directly subjected to a
pre-amplification step using the miScript PreAMP PCR kit and
specific validation primer mixes. The procedure was carried out
according to the manufacturer’s protocol with a denaturation
step at 95◦C for 15min, followed by 12 cycles at 94◦C for 30 s
and 60◦C for 3min. 5 µl of diluted pre-amplified product was
used according to the manufacturer’s protocol, with miScript
SYBR Green PCR Kit and individual miScript Primer Assay
for qPCR on the CFX384 BioRad Real-Time PCR System
following the same amplification steps as carried out for the
QC cel-miR-39 qPCR. Samples were measured in duplicate.
Relative expression levels of miRNAs were calculated using
the comparative CT (2-11CT) method for specific miScript
validation experiments, where CT is cycle threshold, and 1Ct =
CT (miRNA)−CT (referencemiRNA). Reference/normalization
miRNAs were chosen based on their stable expression across
sample groups demonstrated in the small RNA sequencing data
analysis and through previously published literature. These 7
reference/normalization candidates (cel-miR-39, RNU6, miR-
204-5p, miR-10a-5p, miR-10b-5p, miR-30a-5p, SNORD95) were
first investigated by qPCR to ascertain stability across the
investigated samples prior to the subsequent candidate miRNA
qPCR validation. All statistical analysis between two comparison
groups was carried out using the unpaired two-tailed t-tests in
GraphPad Prism version 7.
RESULTS
Individual Sample Quality Control
Testing–Pre-sequencing
Pre-sequencing extracted samples were analyzed via qPCR for the
cel-miR-39 spike-in. No significant difference was identified in
the levels of cel-miR-39 between the control and sALS extracted
CSF samples and therefore all samples were viable for small RNA
sequencing (Figure 2).
Individual Sample Quality Control
Testing–Post-sequencing
Initial post-sequencing QC analysis was carried out using the
Illumina Sequencing Analysis Viewer and Chimira. Each sample
was run in duplicate across two lanes of the flow cell to maximize
the read coverage. Using the methodology parameters, we got an
FIGURE 2 | miRNA recovery of cel-miR-39 after miRVana PARIS extraction
using Qiagen miScript qPCR. Ct values were compared across the control and
sALS samples where the lowest Ct value indicates the highest amount of
miRNA recovery. No significant difference in cel-miR-39 levels was seen
between control and sALS samples. Ct, cycle threshold; CSF, cerebrospinal
fluid; sALS, sporadic amyotrophic lateral sclerosis; ns, non-significant.
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average of 132–208 clusters per mm2 per flow cell lane. The Q30
scores remained above 97.5% throughout the sequencing run
with an average of 3,202,323 (658,761–10,348,286) combined PF
reads per sample identified. Chimira uses inputted sequences and
maps these against miRBase_v21 in order to decipher the miRNA
expression content in the input samples. Chimira identified a
spread of miRNA mapped read counts ranging from 4,809 to
734,672 across the samples. In doing this 8 outlier samples
(Figure 3A red asterisk) were easily identified, this accounted for
3 sALS cases and 3 control subjects. These particular samples
were removed to reveal more comparable samples ranging from
4,809 to 74,004 read counts (Figure 3B). These samples were
taken forward for further interrogation in both Oasis 2.0 and
Genboree analysis platforms.
Oasis 2.0 and Genboree miRNA Expression
Profiling
We carried out downstream analysis using two bioinformatics
platforms Oasis 2.0 and Genboree. When analyzing the data
from all the sequenced CSF samples simultaneously we detected
179 different miRNAs expressed at least once via Oasis 2.0 and
274 different miRNAs via Genboree. The top 30 most abundant
miRNAs as identified by Oasis 2.0 and Genboree from all the
CSF samples are presented inTable 2. The complete list of known
miRNAs identified by both platforms for all analyzed samples is
provided in Supplementary Tables 1 and 2.
miRNAs Are Differentially Expressed in
sALS Patients
Initial data analysis was carried out to investigate whether any
statistical differences in miRNA expression existed between the
two control groups. There were only 4 miRNAs identified as
significantly different between the neurological disease controls
(MS cases) and healthy control cases (headache/migraine
cases); miR-142-5p, let-7g-5p, miR-150-5p, and miR-4486
(Supplementary Tables 1 and 2). However, neither let-7g-5p nor
miR-4486 were identified as significantly different between either
control group comparisons with sALS patients. miR-142-5p and
miR-150-5p were identified as significantly downregulated in
the sALS cases compared to the healthy control group and a
non-significant down regulation in these two miRNAs was also
identified in sALS cases when compared to the neurological
disease controls (MS group). Consequently, this suggests that
analyzing the data by including the neurological disease control
cases (MS cases) with the healthy control subjects maintained the
differences in miRNA expression and helped to increase control
cohort size and significance and therefore all further analysis was
carried out combining the two control groups, known as the
“combined control” cohort.
The sample data from the combined control group and sALS
patient group were subjected to miRNA differential expression
analysis via both Genboree and Oasis 2.0 platforms using
DeSeq2. Significant differential expression was determined in
sALS patients compared to control subjects. Results were filtered
at corrected p < 0.05 and normalized mean >5 mapped reads.
Eleven significant miRNAs were determined in both analysis
platforms (Figure 4) with an additional 33 significant miRNA
changes determined specifically by Oasis 2.0 and one additional
significant miRNA change determined specifically by Genboree.
Only those significant miRNA changes with read abundance calls
>50 were considered for validation (7/11 common miRNAs)
withmiR-124 also added to the candidate list due to its previously
established role in the brain (Cheng et al., 2009; Maiorano
and Mallamaci, 2010). An additional 7 significantly expressed
miRNAs as determined by Oasis 2.0 analysis were also considered
for validation based on their mean read abundance being >50
and the Genboree analysis for those particular miRNA being just
out of significance, or due to the miRNAs having an already
established role in the brain/neurological disease. In total 15
miRNAs were chosen for validation as outlined in Table 3 and
their function summarized in Table 4. Analysis of miRNA read
count data showed no significant correlation of any of the 15
candidate miRNAs with increasing age in both Genboree and
Oasis (data not shown). Additionally no difference in miRNA
read count was identified between male and female subjects (data
not shown).
Small RNA Sequencing Validation
Using the miScript qPCR system attempts were made to validate
the small RNA sequencing findings. However, there are many
challenges of using qPCR for this application as highlighted
by other studies (Metpally et al., 2013). Despite statistically
significant differences in miRNA expression identified by small
RNA sequencing, qPCR validation failed to replicate this.
However, 7/15 candidates show the same directional change
in the samples as identified in the initial sequencing study
(Supplementary Figure 2).
DISCUSSION
We began our studies with the focus to identify specific miRNA
biomarkers present in the CSF of sALS patients. Our aim
was to use small RNA sequencing to investigate differentially
expressed miRNAs in the CSF of sALS patients compared
with control subjects. Overall, this novel study involved the
optimization of methods involved in RNA extraction, small
RNA sequencing library preparation and relevant quality control
testing of samples. Subsequently we assessed the use of various
different data analysis software packages in order to determine
a pipeline that allowed us to carry out miRNA differential
expression analysis between control subjects and sALS patients.
We tested the robustness of the sequencing data by attempting to
validate the miRNA expression with a second type of detection,
using Qiagen miScript qPCR probes. Candidate miRNAs for
validation were chosen from the significantly expressed miRNAs
showing an average abundance read count of more than 50
across the patient/control groups or based on previous literature
identifying their presence in the nervous system. Around half of
the candidate miRNAs showed the same directional change as
identified in the sequencing study, which however failed to reach
statistical significance. Whilst the candidate miRNAs were not
statistically validated due to technical issues, these miRNAs have
been implicated in the literature.
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FIGURE 3 | Quality control data analysis across CSF small RNA sequenced samples. Each sample was ran in duplicate across two lanes of a sequencing flow cell.
Chimira was used to provide an overall assessment of the miRNA expression content in each sequenced sample across the two lanes. (A) Eight samples showed
read counts that were considerably higher than the remaining 82 samples (* outlier samples), these outlier samples would skew any differential expression analysis. (B)
Upon removal of the 8 outlier samples each sample read count is now comparable for differential expression analysis.
Our analysis revealed the upregulation of a number of
miRNA, specifically associated with a known CNS presence;
miR-124-3p, miR-9-5p, miR-125b-2-3p, and miR-27b-3p. miR-
124 is one of the most highly expressed miRNAs in the CNS
(Cheng et al., 2009; Meza-Sosa et al., 2014) and has been
associated with maintaining neuronal cell identity (Maiorano
and Mallamaci, 2010) and synaptic plasticity (Rajasethupathy
et al., 2009). miR-9 is an evolutionary-conserved brain enriched
miRNA (Meza-Sosa et al., 2014), while miR-125b is a known
regulator of glia (Smirnova et al., 2005) and has been associated
with astrogliosis (Pogue et al., 2010) and microgliosis linked to
neuroinflammation in ALS (Parisi et al., 2013). miR-27b-3p is
highly expressed in the brain and has been linked to bipolar
disorder and schizophrenia (Moreau et al., 2011).
The upregulation of miR-9, miR-124 and miR-125b have been
found in the brain of ALS mice at late disease stage (Marcuzzo
et al., 2015), with miR-124 and miR-9 linked to neural activity
and miR-125b linked to the corticospinal tract degeneration in
ALS (Marcuzzo et al., 2015). Previous studies have suggested
that a failure of cell cycle regulation could lead to the post-
mitotic motor neurones attempting to re-enter the cell cycle,
leading to cell death associated with the disease. Therefore,
increased expression of these three particular miRNAs has been
suggested to result from brain injury due to neurological disease.
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TABLE 2 | Top 30 most abundant miRNAs identified in human CSF samples analyzed by Oasis 2.0 and Genboree.
Rank Oasis 2.0 Base Mean read count Rank Genboree Base Mean read count
1 cel-miR-39-3p 5,5561 1 hsa-miR-204-5p 5,448
2 hsa-miR-204-5p 2,951 2 hsa-miR-143-3p 3,882
3 hsa-miR-143-3p 2,111 3 hsa-miR-10b-5p 2,327
4 hsa-miR-125b-2-3p 1,455 4 hsa-miR-486-5p 2,139
5 hsa-miR-10b-5p 1,202 5 hsa-miR-181a-5p 1,702
6 hsa-miR-181a-5p 906 6 hsa-miR-125b-2-3p 1,424
7 hsa-miR-92a-3p 605 7 hsa-miR-92a-3p 1,190
8 hsa-miR-27b-3p 604 8 hsa-miR-10a-5p 1,091
9 hsa-miR-10a-5p 561 9 hsa-miR-27b-3p 1,047
10 hsa-miR-30a-5p 514 10 hsa-miR-30a-5p 993
11 hsa-miR-125b-5p 464 11 hsa-miR-22-3p 882
12 hsa-miR-22-3p 460 12 hsa-let-7f-5p 704
13 hsa-miR-486-5p 377 13 hsa-miR-26a-5p 589
14 hsa-let-7f-5p 369 14 hsa-miR-21-5p 566
15 hsa-miR-26a-5p 361 15 hsa-let-7a-5p 487
16 hsa-miR-21-5p 304 16 hsa-miR-92b-3p 477
17 hsa-let-7a-5p 245 17 hsa-miR-423-5p 460
18 hsa-miR-92b-3p 242 18 hsa-miR-30d-5p 241
19 hsa-miR-30d-5p 127 19 hsa-miR-101-3p 222
20 hsa-miR-101-3p 123 20 hsa-miR-155-5p 205
21 hsa-miR-155-5p 117 21 hsa-let-7i-5p 203
22 hsa-let-7i-5p 105 22 hsa-miR-148a-3p 189
23 hsa-miR-148a-3p 103 23 hsa-miR-151a-3p 169
24 hsa-miR-9-5p 93 24 hsa-miR-9-5p 164
25 hsa-miR-151a-3p 89 25 hsa-miR-191-5p 155
26 hsa-miR-30e-5p 80 26 hsa-miR-30e-5p 154
27 hsa-miR-191-5p 80 27 hsa-miR-16-5p 152
28 hsa-miR-16-5p 78 28 hsa-miR-146a-5p 148
29 hsa-miR-28-3p 77 29 hsa-let-7c-5p 143
30 hsa-miR-146a-5p 74 30 hsa-miR-28-3p 142
Consequently, the increased expression of miR-124-3p and miR-
9-5p in sALS patient CSF could reflect neuronal injury and cell
death, while an increase in miR-125b may represent a by-product
of neuroinflammation and gliosis occurring in the brain during
disease (Parisi et al., 2013).
An increase in the plasma concentration of miR-124 was seen
8 h after surgery to produce brain injury in a rat stroke model
and peaked at 24 h, suggesting that circulating miR-124-3p is a
marker of brain injury (Laterza et al., 2009). In stroke, a series
of pathological changes results in damage to brain cells and it
is suggested these products of cellular damage are released into
circulation. Evidently, as ALS pathogenesis involves the death of
motor neurones and increase in gliosis, the increased expression
of both neural markers miR-124 and miR-9 and the glial marker
miR-125b in the CSF could be used as a marker of brain injury,
more specifically neuronal death and gliosis associated with the
disease. Additionally, the highly expressed brain miRNA, miR-
127-3p, was also increased in the CSF of our sALS patients. An
increased expression of miR-127-3p has previously been reported
in primary cultured spinal neurones leading to neuronal loss,
neurodegeneration and neuronal apoptosis (He et al., 2016a).
Investigating whether the expression of these miRNAs
continues to increase in the CSF over the disease course
will be crucial as to the value of these CSF miRNAs as
useful biomarkers of disease progression, and their potential as
prognostic indicators.
Recently we reported the increased expression of miR-143-
3p in sALS patient serum samples, suggesting its negative role
on myoblast cell differentiation with increasing expression levels
associated withmuscle denervation (Waller et al., 2017). Likewise
miR-143-3p was also increased in the CSF of sALS patients
in the current study. An increased expression of miR-143-3p
has been identified as playing a role in many different cancers
and it’s over expression linked to an anti-proliferative and pro-
apoptotic role (Borralho et al., 2009; He et al., 2016b; Li et al.,
2017). Therefore, increased expression of miR-143-3p in the
CSF of sALS patients may be a by-product from dying motor
neurones which could further contribute to motor neurone death
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FIGURE 4 | Comparing the significantly expressed miRNAs identified between the two platforms, 11 miRNAs are common between the two as listed. There are more
significantly expressed miRNAs identified by Oasis 2.0 platform. Only those miRNAs that have read counts above 50 were considered for validation.
associated with the disease. Additional functional studies would
be required to investigate this further.
Another highlighted role of miR-143 is in the regulation of
glucose metabolism. Following experimental ischemic injury,
miR-143-3p is significantly induced in rat neurones, and this
has a direct effect on glucose metabolism, suppressing glucose
uptake and lactate production (Zeng et al., 2017). Equally,
glycolysis enzymes hexokinase 2 (HK2), pyruvate kinase muscle
isozyme M2 (PKM2) and lactate dehydrogenase A (LDHA) were
also inhibited by experimental ischemic injury, with the over
expression of miR-143-3p further inhibiting HK2, glucose uptake
and lactate production (Zeng et al., 2017). HK2 is a direct
target of miR-143-3p, hence restoring HK2 activity in miR-143-
3p over expressing neurones rescued glucose uptake and lactate
production (Zeng et al., 2017). Our current study also identified
a down regulation of miR-142-5p, an important regulator of cell
survival. In a cellular model of neuronal ischemia/reperfusion
injury, miR-142-5p was induced in the hippocampal neurones.
Inhibition of miR-142-5p reduced cell injury and oxidative stress
in the model by upregulating the Nrf2/ARE signaling pathway
(Wang et al., 2017). Evidently, the down regulation of miR-142-
5p in our current study may work to oppose the upregulation
of miR-143-3p in an attempt to regulate further neuronal loss
and brain injury. Consequently, inhibiting miR-143-3p and
increasing miR-142-5p expression during ischemic brain injury
could help to protect neuronal cells. This represents a possible
therapeutic measure in ALS where metabolic dysregulation
and oxidative stress are considered to play a role in disease
pathogenesis.
A number of miRNAs identified in the current study
by small RNA sequencing were down- regulated in sALS
patients compared to control subjects. However, any functional
implication of this dysregulation in CSF circulating miRNAs in
ALS remains to be investigated.
From the current literature, several possible roles/functions of
these dysregulated miRNAs have been presented. For example
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TABLE 3 | Validation miRNAs.
miRNA Count abundance log2FoldChange (control vs. sALS) Increase/Decrease
Oasis 2.0 Genboree Oasis 2.0 Genboree Control vs. sALS
miR-124-3p 13 24 2.09 3.17 Increased
miR-127-3p 50 89 1.65 1.38 Increased
miR-143-3p 2111 3882 0.58 0.48 Increased
miR-125b-2-3p 1455 1424 0.58 0.62 Increased
miR-9-5p 93 164 1.91 1.64 Increased
miR-27b-3p 604 1047 0.74 0.62 Increased
miR-486-5p 377 2139 −1.13 −0.85 Decreased
Let-7f-5p 369 704 −0.33 −0.42 Decreased
miR-16-5p 78 152 −0.76 −0.77 Decreased
miR-28-3p 77 142 −0.58 −0.59 Decreased
miR-146a-5p 74 148 −0.85 −0.82 Decreased
miR-150-5p 48 95 −1.53 −1.39 Decreased
miR-378a-3p 33 73 −0.9 −0.95 Decreased
miR-142-5p 30 39 −1.23 −1.25 Decreased
miR-92a-5p 605 1190 −0.52 −0.54 Decreased
Values in blue indicate significantly differentially expressed miRNAs that were identified by Oasis 2.0 only. Values in yellow indicate significantly differentially expressed miRNAs that were
identified by both Oasis 2.0 and Genboree. Results were filtered at corrected p-value < 0.05. sALS, sporadic amyotrophic lateral sclerosis.
miR-150-5p and miR-146a are immune-mediated miRNAs with
circulating miR-150-5p increased in the CSF of MS patients
(Bergman et al., 2016) and the serum of MG patients (Punga
et al., 2015). miR-146a-5p, a key regulator of the innate immune
response, was markedly increased in active MS lesions in humans
(Junker et al., 2009). In contrast, the current study identified
decreased expression of both miR-150-5p and miR-146a-5p in
CSF samples of sALS patients. This may be a result of the samples
being taken from patients at particular points in their disease
where neuroinflammation was not at its highest, or perhaps these
miRNAs may have distinct roles that are not yet known.
Additionally miR-378a-3p, which is known to be involved
in myogenesis and regulation of skeletal muscle growth by
promoting myoblast differentiation and inhibiting proliferation
(Wei et al., 2016), is decreased in the CSF samples of sALS
patients. Again, this may suggest an alternative currently
unknown role of the miRNA, specifically within the brain/CSF
environment, in comparison to the periphery.
Cancer related studies have identified the dysregulation of
miR-486-5p in association with many human cancers (Chen
et al., 2015), specifically demonstrating reduced expression linked
to cancer development with studies identifying the role of miR-
486-5p as a tumor suppressor (Oh et al., 2011; Peng et al., 2013).
Therefore, the particular genes and molecular pathways targeted
by miR-486-5p in its tumor suppressant role may play a part in
cell death in neurodegenerative disease and further investigation
is warranted.
A decrease in miR-16-5p was identified in a murine model of
early-onset AD, which linked the reduced levels with increased
levels of amyloid precursor protein (APP). Upon administrating
miR-16-5p into the brains of these mice, APP levels reduced
suggesting a neuroprotective role of miR-16-5p (Liu et al., 2012).
Similarly, a neuroprotective role of miR-16-5p was identified
in the brains from prion-infected mice. These mice presented
an upregulation of miR-16-5p in early pre-clinical disease, with
expression levels reducing with disease progression suggestive of
a neuroprotective role of the miRNA (Majer et al., 2012). It would
be interesting to determine whether in a similar way, miR-16-5p
continues to decrease in sALS patients, corresponding to disease
progression, and investigate the use of this miRNA as a potential
prognostic biomarker.
With only three publications investigating miRNA expression
using small RNA sequencing in CSF samples (Burgos et al.,
2013, 2014; Yagi et al., 2017) there was limited information
available to identify the best technical approach for this work.
Consequently, many optimization studies preceded the final CSF
small RNA sequencing presented in this report. Preliminary
work identifying the most appropriate RNA extraction method
to obtain an enriched level of miRNA had to be completed.
In CSF the concentration of RNA is small and therefore the
concentration of miRNA is even more limited and measuring
miRNA concentration is problematic as previously reported
(Buschmann et al., 2016). Prior investigations as to which library
preparation kit was optimal for CSF samples were also completed.
In addition, a number of further technical aspects to the
methodology were assessed including: how to load each sample
onto the sequencing flow cell (single or pooled), determining
how many barcoded samples to load per lane of a flow cell, and
the concentration of pooled samples to load to achieve optimal
cluster density had to be established, along with the optimal
method for data analysis.
Overall, considering all of the miRNAs that were most
abundant in our CSF samples, our results were consistent
with the other CSF small RNA sequencing publications where
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TABLE 4 | A summary of the candidate validation miRNAs and their known function.
miRNA Description References
miR-124-3p • A highly expressed miRNA in the CNS Cheng et al., 2009; Meza-Sosa et al., 2014
• Involved in maintaining neuronal cell identity Maiorano and Mallamaci, 2010
• Involved in maintaining synaptic plasticity Rajasethupathy et al., 2009
• Found in the brain of ALS mice at late stage disease, with miR-9 and miR-125
linked to neural activity
Marcuzzo et al., 2015
• A suggestive marker of brain injury in a rat stroke model Laterza et al., 2009
miR-127-3p • Linked to neuronal loss, neurodegeneration and apoptosis in primary cultured
spinal neurones
He et al., 2016a
miR-143-3p • Found to have a negative role on myoblast differentiation with increasing levels
associated with muscle denervation Du et al., 2016
• Increased levels found in serum of sALS patients Waller et al., 2017
• Increased levels linked to an anti-proliferative and pro-apoptotic role Borralho et al., 2009; He et al., 2016b; Li et al., 2017
• Found to be induced in rat neurones, associated in the regulation of glucose
metabolism in experimental ischemic injury
Zeng et al., 2017
miR-125b-2-3p • A known regulator of glia, associated with astrogliosis Smirnova et al., 2005; Pogue et al., 2010
• Associated with microgliosis and linked to neuroinflammation in ALS Parisi et al., 2013
• Found in the brain of ALS mice at late stage disease along with miR-124 and
miR-9 linked to corticospinal tract degeneration in ALS
Marcuzzo et al., 2015
• Circulating miR-125b and miR-9 was downregulated with miR-9 in an APP/PS1
transgenic mouse model of AD. A potential biomarker
Hong et al., 2017
miR-9-5p • A brain enriched miRNA Meza-Sosa et al., 2014
• Found in the brain of ALS mice at late stage disease with miR-124 and miR-125
linked to neural activity
Marcuzzo et al., 2015
• Circulating miR-9 and miR-125b was downregulated in an APP/PS1 transgenic
mouse model of AD. A potential biomarker
Hong et al., 2017
miR-27b-3p • A highly expressed miRNA in the brain linked to bipolar disorder and schizophrenia Moreau et al., 2011
miR-486-5p • Dysregulated in many human cancers, acting as a tumor suppressor Oh et al., 2011; Peng et al., 2013
miR-16-5p • Reduced levels identified in a murine model of early-onset AD, linking reduced
levels with increased levels of amyloid precursor protein (APP)
Liu et al., 2012
• A neuroprotective role in prion infected mice Majer et al., 2012
miR-28-3p • Circulating miR-28-3p was upregulated in an APP/PS1 transgenic mouse model of
AD. A potential biomarker
Hong et al., 2017
miR-146a • An immune-mediated miRNA, a key regulator of the innate immune response
increased in active MS lesions in humans
Junker et al., 2009
miR-150-5p • An immune-mediated miRNA, circulating miR-150-5p increased in CSF of MS
patients and serum of MG patients
Punga et al., 2015; Bergman et al., 2016
miR-378a-3p • Involved in myogenesis and regulation of skeletal muscle growth, promoting
myoblast differentiation and inhibiting proliferation
Wei et al., 2016
miR-142-5p • An important regulator of cell survival. In a neuronal ischemic injury cell model
miR-142-5p was induced by neurones. Inhibition of miR-142-5p reduced cell injury
and oxidative stress in the model by upregulating the Nrf2/ARE signaling pathway
Wang et al., 2017
miR-92a-3p • miR-92a-3p linked to white matter impairment and post-stroke depression He et al., 2017
CNS, central nervous system; AD, Alzheimer’s disease; sALS, sporadic amyotrophic lateral sclerosis; MS, multiple sclerosis; MG, myasthenia gravis.
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miR-204-5p was most highly abundant and most probably a CSF
enriched miRNA (Burgos et al., 2013; Yagi et al., 2017). Also,
our main findings were supported by the published literature
describing detection ofmiRNAs includingmiR-486-5p,miR-143-
3p miR-10a-5p, and miR-10b-5p represented within the top 10
most abundantly expressed miRNA in CSF (Burgos et al., 2013;
Yagi et al., 2017). We therefore propose that the experimental
strategy and analysis pipeline we followed is robust.
On the whole, there is little surprise that the differentially
expressed miRNAs determined in this current study contrast
with those we found in our previous work investigating serum
based miRNAs as potential biomarkers of ALS (Waller et al.,
2017). Not only do we use different technologies to assess
miRNA expression, the implications of which are discussed in
the current paper, but the two studies investigate very different
biological fluids. As a miRNAs role is to rapidly and reversibly
respond, their expression and ultimate function will be constantly
changing and affected by many outside influences including a
person’s diet, lifestyle choice, etc. Clearly, since CSF is separated
from blood circulation by the blood–brain barrier, the expression
of CSF based miRNA will be influenced by different factors
to those serum based miRNAs. For example, lower motor
neuron axons reside outside of the CNS and so changes may
be seen in the serum, which are not detected in the CSF.
Undoubtedly, this will contribute to the contrast in miRNAs
found in our studies and others (Burgos et al., 2013; Raoof et al.,
2017).
Despite qPCR being used routinely as a methodology for
validating gene expression microarray results, its ability to
validate CSF based small RNA sequencing data is less reliable
and an alternative method for validation is required. There
are many reasons why qPCR may not be sufficient to validate
small RNA sequencing data: (1) The sensitivity of qPCR is
lower than in sequencing; (2) The miScript primer assays used
in the validation qPCRs could lead to cross reactivity due
to the small size of miRNAs. Hence any slight change in
one or two nucleotides distinguishing between two separate
miRNAs may not be picked up by qPCR; (3) The small
size of miRNAs restricts the designing of optimized primers;
(4) As identified in many miRNA expression studies, the
normalization of data remains a controversial issue (Metpally
et al., 2013; Muller et al., 2014; Benigni et al., 2016; Lusardi
et al., 2017). In this study, we tried to approach the normalization
issue in a methodical way by examining the sequencing
read counts to identify the miRNAs that appeared constant
across all samples analyzed. Prior to any downstream qPCR
experiments the stability of 6 potential normalization miRNAs
were investigated in our samples using the miScript qPCR
system, and subsequently 2 normalization miRNAs were chosen
for all the downstream qPCR investigations (cel-miR-39 and
miR-30a-5p). Despite this, sequencing and qPCR are very distinct
platforms with variability in sample preparation, normalization
and reference gene selection contributing to these different
results. Other factors that could influence study outcomes
include insufficient sized cohorts, differences in sample reagents,
differences in baseline miRNA levels due to age, disease
progression or other epidemiological reasons (Lusardi et al.,
2017). It is interesting to note that from all CSF based small
RNA sequencing studies performed, none of the findings have
been statistically validated using qPCR. Instead, the approach
by many for profiling miRNA expression in CSF has been
to use miRNA qPCR array plates, confirming findings using
individual qPCR i.e., the same technology (Benigni et al., 2016;
Akers et al., 2017; Lusardi et al., 2017; Quintana et al., 2017).
Consequently, with future sequencing experiments, validation
may be best suited to repeating the small RNA sequencing on
an additional validation patient cohort to investigate whether
the candidate miRNAs identified in the discovery cohort are
replicated in the validation cohort. Inevitably, this approach
would be limited by the availability of additional patient samples
and the cost implications of running additional sequencing
experiments.
Overall, the presence of differentially expressedmiRNAs in the
CSF of sALS patients compared to control subjects opens up a
whole new field of understanding the pathophysiological basis
of disease. Identifying the presence of a group of dysregulated
miRNAs in the CSF of sALS patients could help in disease
stratification and as prognostic indicators. In turn, looking at the
expression of particular miRNAs during a patient’s disease course
could help to identify how well a particular therapy is working
for that patient. In addition, this will help to identify sub groups
of patients that may benefit/respond better to a specific therapy
with the potential to open up the realm of personalized medicine
for ALS.
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Supplementary Figure 1 | Quality control testing of CSF small RNA sequencing
library preparations. (A) A typical small RNA bioanalyzer trace of a miRVana PARIS
extracted CSF sample (red, approximately 22nt) aligned with the small RNA ladder
(blue). (B) A High sensitivity DNA bioanalyzer chip trace showing the CSF cDNA
amplicon after 15 cycles of PCR amplification and the gel insert identifying the
corresponding miRNA band in each sample (black box) during library preparation.
(C) A High sensitivity DNA bioanalyzer chip trace showing the purified amplified
CSF cDNA library construct, the 142 bp peak primarily containing mature
microRNA generated from approximately 22 nt small RNA fragments. This sample
is now ready for subsequent sample pooling and cluster generation.
Supplementary Figure 2 | miRNA qPCR validation. From the candidate miRNAs
identified as statistically significantly expressed in sALS patients using small RNA
sequencing, 7/15 miRNAs showed a non-significant same directional change
when investigated using qPCR (A,E,G,I,L–N). The remaining 8/15 miRNAs
showed very little change between sALS patients and control subjects using
qPCR (B–D,F,H,J,K,O).
Supplementary Table 1 | Raw read counts generated by OASIS 2.0.
Supplementary Table 2 | Raw read counts generated by Genboree.
REFERENCES
Akers, J. C., Hua, W., Li, H., Ramakrishnan, V., Yang, Z., Quan, K., et al. (2017).
A cerebrospinal fluid microRNA signature as biomarker for glioblastoma.
Oncotarget. 8, 68769–68779. doi: 10.18632/oncotarget.18332
Anders, S., and Huber, W. (2010). Differential expression analysis for sequence
count data. Genome Biol. 11:R106. doi: 10.1186/gb-2010-11-10-r106
Benatar, M., and Wuu, J. (2012). Presymptomatic studies in ALS:
rationale, challenges, and approach. Neurology 79, 1732–1739.
doi: 10.1212/WNL.0b013e31826e9b1d
Benigni, M., Ricci, C., Jones, A. R., Giannini, F., Al-Chalabi, A., and Battistini,
S. (2016). Identification of miRNAs as potential biomarkers in cerebrospinal
fluid from amyotrophic lateral sclerosis patients. Neuromol. Med. 18, 551–560.
doi: 10.1007/s12017-016-8396-8
Bergman, P., Piket, E., Khademi, M., James, T., Brundin, L., Olsson,
T., et al. (2016). Circulating miR-150 in CSF is a novel candidate
biomarker for multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm.
3:e219. doi: 10.1212/NXI.0000000000000219
Borralho, P. M., Kren, B. T., Castro, R. E., Da Silva, I. B., Steer, C. J., and Rodrigues,
C. M. (2009). MicroRNA-143 reduces viability and increases sensitivity to 5-
fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 276, 6689–6700.
doi: 10.1111/j.1742-4658.2009.07383.x
Burgos, K. L., Javaherian, A., Bomprezzi, R., Ghaffari, L., Rhodes, S.,
Courtright, A., et al. (2013). Identification of extracellular miRNA in
human cerebrospinal fluid by next-generation sequencing. RNA 19, 712–722.
doi: 10.1261/rna.036863.112
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T.,
et al. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and
serum from patients with Alzheimer’s and Parkinson’s diseases correlate
with disease status and features of pathology. PLoS ONE 9:e94839.
doi: 10.1371/journal.pone.0094839
Buschmann, D., Haberberger, A., Kirchner, B., Spornraft, M., Riedmaier, I.,
Schelling, G., et al. (2016). Toward reliable biomarker signatures in the age of
liquid biopsies - how to standardize the small RNA-Seq workflow.Nucleic Acids
Res. 44, 5995–6018. doi: 10.1093/nar/gkw545
Capece, V., Garcia Vizcaino, J. C., Vidal, R., Rahman, R. U., Pena Centeno,
T., Shomroni, O., et al. (2015). Oasis: online analysis of small RNA deep
sequencing data. Bioinformatics 31, 2205–2207. doi: 10.1093/bioinformatics/
btv113
Chen, H., Ren, C., Han, C., Wang, D., Chen, Y., and Fu, D. (2015). Expression and
prognostic value of miR-486-5p in patients with gastric adenocarcinoma. PLoS
ONE 10:e0119384. doi: 10.1371/journal.pone.0119384
Cheng, L. C., Pastrana, E., Tavazoie, M., and Doetsch, F. (2009). miR-124 regulates
adult neurogenesis in the subventricular zone stem cell niche.Nat. Neurosci. 12,
399–408. doi: 10.1038/nn.2294
Coarfa, C., Pichot, C., Jackson, A., Tandon, A., Amin, V., Raghuraman,
S., et al. (2014). Analysis of interactions between the epigenome
and structural mutability of the genome using Genboree Workbench
tools. BMC Bioinformatics 15(Suppl. 7):S2. doi: 10.1186/1471-2105-15-
S7-S2
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., and Jahn, H. (2015).
MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer’s
disease. PLoS ONE 10:e0126423. doi: 10.1371/journal.pone.0126423
Drusco, A., Bottoni, A., Lagana, A., Acunzo, M., Fassan, M., Cascione, L.,
et al. (2015). A differentially expressed set of microRNAs in cerebro-spinal
fluid (CSF) can diagnose CNS malignancies. Oncotarget 6, 20829–20839.
doi: 10.18632/oncotarget.4096
Du, J., Zhang, Y., Shen, L., Luo, J., Lei, H., Zhang, P., et al. (2016). Effect of
miR-143-3p on C2C12myoblast differentiation. Biosci. Biotechnol. Biochem. 80,
706–711. doi: 10.1080/09168451.2015.1123604
Freischmidt, A., Muller, K., Ludolph, A. C., and Weishaupt, J. H. (2013). Systemic
dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis.
Acta Neuropathol. Commun. 1:42. doi: 10.1186/2051-5960-1-42
Ghasemi, M. (2016). Amyotrophic lateral sclerosis mimic syndromes. Iran J.
Neurol. 15, 85–91.
Gui, Y., Liu, H., Zhang, L., Lv, W., and Hu, X. (2015). Altered microRNA profiles
in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
Oncotarget 6, 37043–37053. doi: 10.18632/oncotarget.6158
He, J. R., Zhang, Y., Lu, W. J., Liang, H. B., Tu, X. Q., Ma, F. Y., et al. (2017). Age-
related frontal periventricular white matter hyperintensities and miR-92a-3p
are associated with early-onset post-stroke depression. Front. Aging Neurosci.
9:328. doi: 10.3389/fnagi.2017.00328
He, Q. Q., Xiong, L. L., Liu, F., He, X., Feng, G. Y., Shang, F. F., et al. (2016a).
MicroRNA-127 targeting of mitoNEET inhibits neurite outgrowth, induces
cell apoptosis and contributes to physiological dysfunction after spinal cord
transection. Sci. Rep. 6:35205. doi: 10.1038/srep35205
He, Z., Yi, J., Liu, X., Chen, J., Han, S., Jin, L., et al. (2016b). MiR-143-3p
functions as a tumor suppressor by regulating cell proliferation, invasion and
epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous
cell carcinoma.Mol. Cancer 15:51. doi: 10.1186/s12943-016-0533-3
Hong, H., Li, Y., and Su, B. (2017). Identification of circulating miR-125b as a
potential biomarker of Alzheimer’s disease in APP/PS1 transgenic mouse. J.
Alzheimers. Dis. 59, 1449–1458. doi: 10.3233/JAD-170156
Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R.,
et al. (2009). MicroRNA profiling of multiple sclerosis lesions identifies
modulators of the regulatory protein CD47. Brain 132, 3342–3352.
doi: 10.1093/brain/awp300
Laterza, O. F., Lim, L., Garrett-Engele, P.W., Vlasakova, K., Muniappa, N., Tanaka,
W. K., et al. (2009). Plasma MicroRNAs as sensitive and specific biomarkers of
tissue injury. Clin. Chem. 55, 1977–1983. doi: 10.1373/clinchem.2009.131797
Li, D., Hu, J., Song, H., Xu, H., Wu, C., Zhao, B., et al. (2017). miR-143-3p
targeting LIM domain kinase 1 suppresses the progression of triple-negative
breast cancer cells. Am. J. Transl. Res. 9, 2276–2285.
Liu, W., Liu, C., Zhu, J., Shu, P., Yin, B., Gong, Y., et al. (2012). MicroRNA-
16 targets amyloid precursor protein to potentially modulate Alzheimer’s-
associated pathogenesis in SAMP8 mice. Neurobiol. Aging 33, 522–534.
doi: 10.1016/j.neurobiolaging.2010.04.034
Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:550.
doi: 10.1186/s13059-014-0550-8
Frontiers in Neuroscience | www.frontiersin.org 12 January 2018 | Volume 11 | Article 731
Waller et al. miRNAs in ALS CSF Samples
Lusardi, T. A., Phillips, J. I., Wiedrick, J. T., Harrington, C. A., Lind, B.,
Lapidus, J. A., et al. (2017). MicroRNAs in human cerebrospinal fluid
as biomarkers for Alzheimer’s disease. J. Alzheimers. Dis. 55, 1223–1233.
doi: 10.3233/JAD-160835
Maiorano, N. A., and Mallamaci, A. (2010). The pro-differentiating role of
miR-124: indicating the road to become a neuron. RNA Biol. 7, 528–533.
doi: 10.4161/rna.7.5.12262
Majer, A., Medina, S. J., Niu, Y., Abrenica, B., Manguiat, K. J., Frost, K. L.,
et al. (2012). Early mechanisms of pathobiology are revealed by transcriptional
temporal dynamics in hippocampal CA1 neurons of prion infected mice. PLoS
Pathog. 8:e1003002. doi: 10.1371/journal.ppat.1003002
Marcuzzo, S., Bonanno, S., Kapetis, D., Barzago, C., Cavalcante, P., D’alessandro,
S., et al. (2015). Up-regulation of neural and cell cycle-related microRNAs in
brain of amyotrophic lateral sclerosis mice at late disease stage.Mol. Brain 8:5.
doi: 10.1186/s13041-015-0095-0
Marques, T. M., Kuiperij, H. B., Bruinsma, I. B., Van Rumund, A., Aerts,
M. B., Esselink, R. A., et al. (2016). MicroRNAs in cerebrospinal fluid as
potential biomarkers for Parkinson’s disease and multiple system atrophy.Mol.
Neurobiol. 54, 7736–7745. doi: 10.1007/s12035-016-0253-0
McAlexander, M. A., Phillips, M. J., and Witwer, K. W. (2013). Comparison
of methods for miRNA extraction from plasma and quantitative recovery of
RNA from cerebrospinal fluid. Front. Genet. 4:83. doi: 10.3389/fgene.2013.
00083
Metpally, R. P., Nasser, S., Malenica, I., Courtright, A., Carlson, E.,
Ghaffari, L., et al. (2013). Comparison of analysis tools for miRNA high
throughput sequencing using nerve crush as a model. Front. Genet. 4:20.
doi: 10.3389/fgene.2013.00020
Meza-Sosa, K. F., Pedraza-Alva, G., and Perez-Martinez, L. (2014).
microRNAs: key triggers of neuronal cell fate. Front. Cell. Neurosci. 8:175.
doi: 10.3389/fncel.2014.00175
Moreau, M. P., Bruse, S. E., David-Rus, R., Buyske, S., and Brzustowicz, L. M.
(2011). Altered microRNA expression profiles in postmortem brain samples
from individuals with schizophrenia and bipolar disorder. Biol. Psychiatry 69,
188–193. doi: 10.1016/j.biopsych.2010.09.039
Muller, M., Kuiperij, H. B., Claassen, J. A., Kusters, B., and Verbeek, M.
M. (2014). MicroRNAs in Alzheimer’s disease: differential expression in
hippocampus and cell-free cerebrospinal fluid. Neurobiol. Aging 35, 152–158.
doi: 10.1016/j.neurobiolaging.2013.07.005
Oh, H. K., Tan, A. L., Das, K., Ooi, C. H., Deng, N. T., Tan, I. B., et al.
(2011). Genomic loss of miR-486 regulates tumor progression and the OLFM4
antiapoptotic factor in gastric cancer. Clin. Cancer Res. 17, 2657–2667.
doi: 10.1158/1078-0432.CCR-10-3152
Parisi, C., Arisi, I., D’ambrosi, N., Storti, A. E., Brandi, R., D’onofrio, M.,
et al. (2013). Dysregulated microRNAs in amyotrophic lateral sclerosis
microglia modulate genes linked to neuroinflammation. Cell Death Dis. 4:e959.
doi: 10.1038/cddis.2013.491
Peng, Y., Dai, Y., Hitchcock, C., Yang, X., Kassis, E. S., Liu, L., et al. (2013). Insulin
growth factor signaling is regulated by microRNA-486, an underexpressed
microRNA in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 15043–15048.
doi: 10.1073/pnas.1307107110
Pogue, A. I., Cui, J. G., Li, Y. Y., Zhao, Y., Culicchia, F., and Lukiw, W.
J. (2010). Micro RNA-125b (miRNA-125b) function in astrogliosis and
glial cell proliferation. Neurosci. Lett. 476, 18–22. doi: 10.1016/j.neulet.2010.
03.054
Punga, A. R., Andersson, M., Alimohammadi, M., and Punga, T. (2015).
Disease specific signature of circulating miR-150-5p and miR-21-5p in
myasthenia gravis patients. J. Neurol. Sci. 356, 90–96. doi: 10.1016/j.jns.2015.
06.019
Quintana, E., Ortega, F. J., Robles-Cedeno, R., Villar, M. L., Buxo, M., Mercader,
J. M., et al. (2017). miRNAs in cerebrospinal fluid identify patients with MS
and specifically those with lipid-specific oligoclonal IgM bands.Mult. Scler. 23,
1716–1726. doi: 10.1177/1352458516684213
Rajasethupathy, P., Fiumara, F., Sheridan, R., Betel, D., Puthanveettil, S. V., Russo,
J. J., et al. (2009). Characterization of small RNAs in Aplysia reveals a role
for miR-124 in constraining synaptic plasticity through CREB. Neuron 63,
803–817. doi: 10.1016/j.neuron.2009.05.029
Raoof, R., Jimenez-Mateos, E. M., Bauer, S., Tackenberg, B., Rosenow, F.,
Lang, J., et al. (2017). Cerebrospinal fluid microRNAs are potential
biomarkers of temporal lobe epilepsy and status epilepticus. Sci. Rep. 7:3328.
doi: 10.1038/s41598-017-02969-6
Riehle, K., Coarfa, C., Jackson, A., Ma, J., Tandon, A., Paithankar, S.,
et al. (2012). The Genboree Microbiome Toolset and the analysis of
16S rRNA microbial sequences. BMC Bioinformatics 13(Suppl. 13):S11.
doi: 10.1186/1471-2105-13-S13-S11
Smirnova, L., Grafe, A., Seiler, A., Schumacher, S., Nitsch, R., and Wulczyn, F. G.
(2005). Regulation of miRNA expression during neural cell specification. Eur.
J. Neurosci. 21, 1469–1477. doi: 10.1111/j.1460-9568.2005.03978.x
Sorensen, S. S., Nygaard, A. B., and Christensen, T. (2016). miRNA expression
profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease
and other types of dementia - an exploratory study. Transl. Neurodegener. 5:6.
doi: 10.1186/s40035-016-0053-5
Subramanian, S. L., Kitchen, R. R., Alexander, R., Carter, B. S., Cheung, K.
H., Laurent, L. C., et al. (2015). Integration of extracellular RNA profiling
data using metadata, biomedical ontologies and linked data technologies. J.
Extracell. Vesicles 4:27497. doi: 10.3402/jev.v4.27497
Vitsios, D. M., and Enright, A. J. (2015). Chimira: analysis of small RNA
sequencing data and microRNA modifications. Bioinformatics 31, 3365–3367.
doi: 10.1093/bioinformatics/btv380
Waller, R., Goodall, E. F., Milo, M., Cooper-Knock, J., Da Costa, M., Hobson,
E., et al. (2017). Serum miRNAs miR-206, 143-3p and 374b-5p as potential
biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol. Aging 55,
123–131. doi: 10.1016/j.neurobiolaging.2017.03.027
Wang, N., Zhang, L., Lu, Y., Zhang, M., Zhang, Z., Wang, K., et al.
(2017). Down-regulation of microRNA-142-5p attenuates oxygen-glucose
deprivation and reoxygenation-induced neuron injury through up-regulating
Nrf2/ARE signaling pathway. Biomed. Pharmacother. 89, 1187–1195.
doi: 10.1016/j.biopha.2017.03.011
Wei, X., Li, H., Zhang, B., Li, C., Dong, D., Lan, X., et al. (2016). miR-
378a-3p promotes differentiation and inhibits proliferation of myoblasts by
targeting HDAC4 in skeletal muscle development. RNA Biol. 13, 1300–1309.
doi: 10.1080/15476286.2016.1239008
Yagi, Y., Ohkubo, T., Kawaji, H., Machida, A., Miyata, H., Goda, S., et al. (2017).
Next-generation sequencing-based small RNA profiling of cerebrospinal fluid
exosomes. Neurosci. Lett. 636, 48–57. doi: 10.1016/j.neulet.2016.10.042
Zeng, X., Liu, N., Zhang, J., Wang, L., Zhang, Z., Zhu, J., et al. (2017). Inhibition of
miR-143 during ischemia cerebral injury protects neurones through recovery
of the hexokinase 2-mediated glucose uptake. Biosci. Rep. 37:BSR20170216.
doi: 10.1042/BSR20170216
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Waller, Wyles, Heath, Kazoka, Wollff, Shaw and Kirby. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 13 January 2018 | Volume 11 | Article 731
